Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis-Reference-Cited by-同舟云学术

Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis

Published:2023-09 Issue: Volume:191 Page:112959
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Padovan Marta^ORCID,Maccari Marta,Bosio Alberto,De Toni Chiara^ORCID,Vizzaccaro Salvatore,Cestonaro Ilaria,Corrà Martina,Caccese Mario^ORCID,Cerretti Giulia,Zagonel Vittorina,Lombardi Giuseppe

Funder

Ministero della Salute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019;Ostrom;Neuro-Oncology,2022

2. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood;Weller;Nat Rev Clin Oncol,2021

3. Comprehensive genomic characterization defines human glioblastoma genes and core pathways;McLendon;Nature,2008

4. The somatic genomic landscape of glioblastoma;Brennan;Cell,2013

5. The 2021 WHO classification of tumors of the central nervous system: a summary;Louis;Neuro Oncol.,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors;npj Precision Oncology;2024-08-14

2. Current status of precision oncology in adult glioblastoma;Molecular Oncology;2024-06-20

3. New Insights into Glioblastoma;International Journal of Molecular Sciences;2024-04-07

4. Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a GOPC::ROS1 fusion;Neuro-Oncology Advances;2024-01-01

5. Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma;Neuro-Oncology Advances;2024-01-01